RoohiIsmail-KhanMDMSC

PubMed

• 97 citations
  Mindfulness-Based Stress Reduction in Post-treatment Breast Cancer Patients: Immediate and Sustained Effects Across Multiple Symptom Clusters
  Richard R. Reich, Cecile A. Lengacher, Carissa B. Alinat, Kevin E. Kip, Carly L. Paterson
  Journal of Pain and Symptom Management. 2017-01-01
• 43 citations
  Developing a Comprehensive Cardio-Oncology Program at a Cancer Institute: The Moffitt Cancer Center Experience.
  Michael G. Fradley, Allen Brown, Bernadette Shields, Federico Viganego, Rongras Damrongwatanasuk
  Oncology Reviews. 2017-07-18
• 224 citations
  Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)
  Raza M. Alvi, Matthew J. Frigault, Michael G. Fradley, Michael D. Jain, Syed S. Mahmood
  Journal of the American College of Cardiology. 2019-12-24

Journal Articles

• Beta-catenin Expression Patterns in Matched Pre and Post Neoadjuvant Chemotherapy Resistant Breast Cancer  
  Rosa M, Han HS, Ismail-Khan R, Allam-Nandyala P, Bui M, Annals of Clinical and Laboratory Science, 1/1/2015
• A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors  
  Soliman HH, Jackson E, Neuger T, Dees C, Harvey D, Han H, Ismail-Khan R, Minton SE, Vahanian N, Link C, Sullivan D, Antonia S, Oncotarget, 1/21/2014
• Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estro...  
  Yardley D, Ismail-Khan R, Trepel J, et al, Journal Of Clinical Oncology, 1/6/2013
• Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy  
  Williams M, Eatrides J, Kim J, Talwar H, Esposito N, Szabunio M, Ismail-Khan R, Kiluk J, Lee M, Laronga C, Khakpour N, Am Jnl of Surgery, 1/1/2013
• Control of brain metastases for HER2-positive breast cancer with bevacizumab: a report of three patients  
  Sajjad M. Pan E, Minton S, Ismail-Khan R, J of Solid Tumors, 1/1/2013
• Randomized trial using the GnRH agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer  
  Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, Xu P, Carter WB, Minton SE, J Clin Oncol, 1/10/2012
• HER2-positive breast cancer in men who also developed thyroid cancer  
  Bardhan P, Bui M, Minton S, Loftus L, Carter WB, Laronga C, Ismail-Khan R, Ann Clin Lab Sci, 1/1/2012
• A Phase I/II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen in patients with hormone-resistant breast cancer  
  Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE, Br J Cancer, 1/7/2011
• Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: a randomized trial using the GnRH agonist (triptorelin) during...  
  Ismail-Khan R, Minton SE, Cox C, et al, J Clin Oncol, 1/1/2008
• Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality  
  Simon GR, Ismail-Khan R, Bepler G, Int J Biochem Cell Biol, 1/1/2007
• Join now to see all

Abstracts/Posters

• A Phase II, open label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC)
  Bardia A, Kummel S, Garcia-Estevez L, Huang CS, Cortes Castan J, Ruiz Borrego M, Telli ML, Lluch Hernandez A, Lopez R, Beck JT, Ismail-Khan R, Chen SC, Hurvitz S, Maye..., ASCO, Chicago, IL, 1/1/2015
• The BCL2 antagonist of cell death (BAD) signaling pathway and phospho-BAD protein levels are associated with triple negative breast cancer clinical development and cli...
  Marchion DC, Xiong Y, Ismail-Khan R, Abbasi F, Bou Zgheib N, Ramirez IJ, Bush SH, Hakam A, Judson PL, Lancaster JM, SGO 45th Annual Meeting, Tampa, FL, 1/21/2014
• AKT survival signaling and phospho-AKT expression are associated with triple negative breast cancer development and clinical outcome
  Marchion DC, Ismail-Khan R, Abbasi F, Boac B, Xiong Y, McClung C, Khulpateea BR, Bush SH, Hakam A, Lancaster JM, SGO 45th Annual Meeting, Tampa, FL, 1/21/2014
• PhaseIb/II study of LEE011, Alpelisib (BYL719), and Letrozole in ER+, HER2-Breast Cancer: Safety, Preliminary Efficacy, and Molecular Analysis
  Juric D, Campone M, Ismail-Khan R, DeBoer R, Garcia Estevez L, Hamilton E, Mayer I, Asano S, Bhansali S, Zhang V, Hewes B, Munster P, SABCS, San Antonio, TX, 1/1/2014
• A phase ½ study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer
  Soliman, H, Minton S, Ismail-Khan R, Han H, Vahanian N, Link C, Kennedy G, Streicher H, Sullivan D, Antonia S, San Antonio Breast Cancer Symposium, 1/1/2014
• Safety and Efficacy of MK-8669 (Ridaforolimus) + MK-2206 (AKT inhibitor) in patients with advanced breast cancer with P13K pathway dependence
  Piha-Paul S, Ismail-Khan R, Munster P, Hollebecque A, Argiles, G, Guren T, Cheng J, Wang R, Swift A, Tosolini A, Sullivan D, Gupta S, IMPAKT, Brussels, Belgium, 1/1/2014
• Prognostic factors and outcomes in triple negative breast cancer – A single institutional experience
  Apuri S, Sun W, Bardhan P, Minton S, Soliman H, Han H, Lee JH, Fulp W, Ismail-Khan R, San Antonio Breast Cancer Symposium, 1/1/2013
• A phase-II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with ...
  Lluch-Hernandez A, Simon AR, Huang C, Castan JC, Ruiz-Borrego M, Telli M, Ismail-Khan R, Parton M, Tseng LM, Chen SC, Schmid P, Mayer I, Hurvitz S, Garcia-Estevez L, A..., San Antonio Breast Cancer Symposium, 1/1/2013
• Triple Negative Breast Cancer and Age: Tumor Characteristics and Outcomes.
  Loftus L, Sokol G, Ismail-Khan R, 13th Conference of the International Society of Geriatric Oncology – SIOG, Copenhagen, Denmark, 1/1/2013
• Increased Risk of Heart Failure in BRCA Mutation Carriers
  Sajjad M, Ismail-Khan R, American Federation of Medical Research, Southern Regional Meetings, New Orleans, LA, 1/1/2012
• A Phase I Study of 1-methyl-D-tryptophan in Combination with Docetaxel in Metastatic Solid Tumors
  Jackson E, Minton SE, Ismail-Khan R, Han HS, Neuger A, Antonia S, Sullivan D, Soliman HH, ASCO, 1/1/2012
• An Exploratory Study to Determine if BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity
  Ismail-Khan R, Sajjad M, Sun W, Soliman HH, Han HS, Minton SE, Lancaster JM, Pal T, ASCO, 1/1/2012
• Exploratory Study to Determine if BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity.
  Ismail-Khan R, Sajjad M, Sun W, Soliman HH, H. Han HS, Minton SE, Lancaster JM, Pal T, International Cardio-Oncology Society Annual Meeting, Milan, Italy, 1/1/2012
• A Phase I Dose Escalation Trial of RO4929097 (y-Secretase Inhibitor) Administered in combination with Exemestane in Pre-and Postmenopausal Patients with ER+/HER 2 Neu-...
  Means-Powell JA, Minton SE, Mayer IA, Abramson VG, Ismail-Khan R, Arteaga CL, Ayers DA, Sanders MS, Lush RM, Miele LL, San Antonio Breast Cancer Symposium, 1/1/2012
• Positive Results of ENCORE-301, A Phase 2 Randomized, Double-blind Placebo-controlled Study in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Recep...
  Yardley DA, Ismail-Khan R, Klein PM, San Antonio Breast Cancer Symposium, 1/1/2011
• Positive Results of ENCORE-301, A Phase 2 Randomized, Double-blind Placebo-controlled Study in Postmenopausal Women with Locally Recurrent or Metastatic Estrogen Recep...
  Yardley DA, Ismail-Khan R, Klein PM, ASCO Breast, 1/1/2011
• A double blind, randomized, placebo controlled phase II study of the steroidal aromatase inhibitor exemestane with and without the isoform selective histone deacetylas...
  Yardley D, Ismail-Khan R, Eakle J, Hagan K, Miller K, Paul D, Borges V, Helsten T, Kroener J, Melichar B, Tkaczuk K, ASCO, 1/1/2011
• Synergy of Ixabepilone and Dasatinib in Triple Negative Breast Cancer Cell Lines
  Ismail-Khan R, Marchion DC, Cubitt CL, Lancaster JM, San Antonio Breast Cancer Symposium, 1/1/2010
• The influence of the BAD apoptosis pathway on breast cancer progression and relapse-free survival after adjuvant treatment
  Ismail-Khan R, Marichion DC, Xiong Y, Fulp WJ, Kamath SG, Eschrich SA, Chen DT, Lancaster JM, San Antonio Breast Cancer Symposium, 1/1/2010
• Modi S, Ismail-Khan R, Munster P, Lucas M, Galluppi GR, Tangri S, Chen Y, Mason Y, Chris MS, Moulder S, San Antonio Breast Cancer Symposium, 1/1/2010
• Urinary Incontinence and its Impact on Quality of Life in Breast Cancer Survivors
  Donovan KA, Boyington AR, Ismail-Khan R, Wyman JF, Moffitt Cancer Center, University of Minnesota, American Psychosocial Oncology Society’s Annual Meeting, New Orleans, LA, 1/1/2010
• Neoadjuvant Intratumoral Injection of Dendritic Cells in Breast Cancer
  Minton S, Gabrilovich D, Lacevic M, Laronga C, Lee C, Kiluk J, Khakpour N, Bui M, Soliman H, Ismail-Khan R, Han H, Munster P, Janssen W, Cowan K, Talmadge J, Reed E, San Antonio Breast Cancer Symposium, 1/1/2009
• Clinical Phase II Study if Vorinostat, a Hydroxamic Deacetylase Inhibitor, in Combination with Tamoxifen To Reverse Acquired Hormone Resistance in Breast Cancer Patien...
  Munster PN, Lacevic M, Thomas S, Ismail-Khan R, Rugo H, Melisko M, Minton SE, San Antonio Breast Cancer Symposium, 1/1/2009
• Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer w...
  Munster PN, Lacevic M, Thomas S, Christian C, Ismail-Khan R, Melisko M, Rugo H, Minton SE, ASCO, 1/1/2009
• Preservation of Ovarian Function in Young Women Treated with (NEO) Adjuvant Chemotherapy for Breast Cancer: A Randomized Trial Using the GnRH Agonist (Triptorelin) Dur...
  Ismail-Khan R, Minton SE, Cox C, Sims I, Lacevic M, Carter B, Munster P, ASCO, 1/1/2008
• Join now to see all

Lectures

• Cardiac Complications from Chemotherapy and The New Cardio-Oncology Program 
  1/12/2015
• Issues in Breast Cancer Therapy 
  University of South Florida, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL - 1/1/2015
• Triple Negative breast cancer 
  1/1/2015
• Advances in Treatment of Metastatic Breast Cancer 
  1/17/2014
• Metaplastic, Medullary and Other Less Common Types of Breast Cancer 
  1/17/2013
• Clinical and Research Advances in Treatment of Breast Cancer 
  Tampa, FL - 1/1/2013
• What is Cancer? 
  1/15/2012
• Breast Cancer – What the Internist Needs to Know 
  Tampa, FL - 1/1/2012
• The Importance of Promoting Breast Cancer Health 
  Tallahassee Memorial Hospital, Tallahassee, FL - 1/10/2011
• Join now to see all

Other

• Cardio-Oncology: An Important New Specialty to Improve Patient Outcomes 
  Ismail-Khan R and Fradley M
  University of South Florida and Moffitt Cancer Center - 1/1/2015
• Triple Negative Breast Cancer 
  Ismail-Khan R, International Hospital and Equipment (IHE), PanGlobal Media
  1/1/2010
• Why Focus on Triple Negative Breast Cancer? 
  Ismail-Khan R, Factors Publications